AMAG Pharmaceuticals (NASDAQ:AMAG) Now Covered by HC Wainwright

Equities researchers at HC Wainwright initiated coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 82.44% from the company’s current price.

Several other equities research analysts also recently weighed in on AMAG. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $9.25 price objective for the company in a research report on Thursday, June 20th. Cowen restated a “hold” rating and issued a $13.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, June 24th. SunTrust Banks set a $13.00 price objective on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, May 14th. Finally, Barclays started coverage on shares of AMAG Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “overweight” rating and a $19.00 price objective for the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $16.83.

Shares of AMAG traded up $0.10 during mid-day trading on Thursday, hitting $8.77. 684,271 shares of the company’s stock were exchanged, compared to its average volume of 727,925. AMAG Pharmaceuticals has a fifty-two week low of $7.81 and a fifty-two week high of $26.10. The company has a 50 day simple moving average of $9.13. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.13 and a current ratio of 2.30.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The business had revenue of $75.80 million for the quarter, compared to analyst estimates of $90.13 million. During the same quarter last year, the company posted ($1.59) EPS. AMAG Pharmaceuticals’s quarterly revenue was down 35.4% on a year-over-year basis. Equities research analysts forecast that AMAG Pharmaceuticals will post -2.13 EPS for the current year.

In related news, insider Elizabeth Scott Bolgiano bought 5,000 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was bought at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the acquisition, the insider now owns 74,847 shares in the company, valued at approximately $818,077.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO William K. Heiden bought 10,000 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was bought at an average cost of $10.70 per share, with a total value of $107,000.00. Following the completion of the acquisition, the chief executive officer now owns 490,056 shares of the company’s stock, valued at approximately $5,243,599.20. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 328,016 shares of company stock valued at $2,904,577. 4.90% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of AMAG. Norges Bank purchased a new position in AMAG Pharmaceuticals in the fourth quarter valued at about $4,454,000. Spark Investment Management LLC increased its holdings in AMAG Pharmaceuticals by 211.1% in the first quarter. Spark Investment Management LLC now owns 371,100 shares of the specialty pharmaceutical company’s stock valued at $4,779,000 after buying an additional 251,800 shares in the last quarter. Acadian Asset Management LLC increased its holdings in AMAG Pharmaceuticals by 25.6% in the first quarter. Acadian Asset Management LLC now owns 682,080 shares of the specialty pharmaceutical company’s stock valued at $8,785,000 after buying an additional 139,134 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new position in AMAG Pharmaceuticals in the second quarter valued at about $803,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in AMAG Pharmaceuticals by 6.4% in the first quarter. Robeco Institutional Asset Management B.V. now owns 1,304,639 shares of the specialty pharmaceutical company’s stock valued at $16,803,000 after buying an additional 79,007 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: Is it Safe to Invest in Commodities?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.